Efficacy of early biopsy in kidney allograft recipients with delayed graft function.
It is accepted that kidney transplants that display delayed graft function (DGF) show poorer survival and function, particularly when an acute rejection episode (ARE) occurs. A diagnostic biopsy to establish the reason for DGF, or acknowledge an ARE, even if borderline, can improve short- and long-term graft survivals. From January 2002 to September 2006 we retrospectively evaluated 358 kidney transplant recipients. We performed a biopsy to evaluate the cause of DGF in all patients who required dialysis, or had serum creatinine levels that increased, remained unchanged, or decreased less than 10% per day on three consecutive days during the first week after transplantation. An ARE was found in 18.8% (n = 19) of the biopsies. Early biopsy for patients with DGF is a safe method that allows uncovering of an ARE that would otherwise be undetected. The immediate recognition and treatment of rejection episodes can certainly increase long-term survival and function of renal transplants.
Puliatti
C
C
Department of Nephrology and Transplant, University Hospital of Wales, Cardiff, UK. carmelo.puliatti@cardiffandvale.wales.nhs.uk
Rizzello
A
A
Ilham
M
M
Asderakis
A
A
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001706:Biopsy; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000473:pathology* / Q000502:physiology*; D013997:Time Factors; D014184:Transplantation, Homologous / Q000473:pathology / Q000502:physiology; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents